Skip to main content
SpringerLink
Log in

Head and Neck Cancer

  • Chapter
Oncology

Abstract

Cancers of the head and neck include a variety of tumors of different histology and behavior. The different subtypes represented by these tumors include squamous cell cancers, paranasal sinus cancers, nasopharyngeal carcinomas, salivary gland cancers, thyroid gland malignancies, melanomas, sarcomas, small cell neuroendocrine carcinoma, and lymphomas. By far the most commonly encountered cancers in this group, accounting for more than 90% of tumors, are the squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx, larynx, and paranasal sinuses. This chapter concentrates on squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), and cancers of the salivary glands

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8–29.

    PubMed  Google Scholar 

  2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827–841.

    Article  PubMed  CAS  Google Scholar 

  3. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.

    Article  PubMed  Google Scholar 

  4. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradio-therapy. Clin Cancer Res 2004;10:1956–1962.

    Article  PubMed  CAS  Google Scholar 

  5. Dhooge IJ, De Vos M, Van Cauwenberge PB. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998;108:250–256.

    Article  PubMed  CAS  Google Scholar 

  6. Reichart PA. Identification of risk groups for oral precancer and cancer and preventive measures. Clin Oral Invest 2001;5:207–213.

    Article  CAS  Google Scholar 

  7. Rodriguez T, Altieri A, Chatenoud L, et al. Risk factors for oral and pharyngeal cancer in young adults. Oral Oncol 2004;40:207–213.

    Article  PubMed  Google Scholar 

  8. Znaor A, Brennan P, Gajalakshmi V, et al. Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men. Int J Cancer 2003;105:681–686.

    Article  PubMed  CAS  Google Scholar 

  9. Winn DM, Blot WJ, Shy CM, Pickle LW, Toledo A, Fraumeni JF Jr. Snuff dipping and oral cancer among women in the southern United States. N Engl J Med 1981;304:745–749.

    Article  PubMed  CAS  Google Scholar 

  10. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195–215.

    PubMed  Google Scholar 

  11. Zhang ZF, Morgenstern H, Spitz MR, et al. Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2000;9:1043–1049.

    PubMed  CAS  Google Scholar 

  12. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995;24:450–453.

    Article  PubMed  CAS  Google Scholar 

  13. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer (Phila) 1953;6:963–968.

    Article  PubMed  CAS  Google Scholar 

  14. Califano J, Leong PL, Koch WM, Eisenberger CF, Sidransky D, Westra WH. Second esophageal tumors in patients with head and neck squamous cell carcinoma: an assessment of clonal relationships. Clin Cancer Res 1999;5:1862–1867.

    PubMed  CAS  Google Scholar 

  15. Califano J, Westra WH, Koch W, et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst 1999;91:599–604.

    Article  PubMed  CAS  Google Scholar 

  16. Syrjanen K, Syrjanen S, Lamberg M, Pyrhonen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983;12:418–424.

    Article  PubMed  CAS  Google Scholar 

  17. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709–720.

    Article  PubMed  CAS  Google Scholar 

  18. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982–1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:622–635.

    PubMed  CAS  Google Scholar 

  19. Snijders PJ, Scholes AG, Hart CA, et al. Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinoma of the head and neck. Int J Cancer 1996;66:464–469.

    Article  PubMed  CAS  Google Scholar 

  20. Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D. Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope 1999;109:1544–1551.

    Article  PubMed  CAS  Google Scholar 

  21. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125–1131.

    Article  PubMed  CAS  Google Scholar 

  22. Van Dyke DL, Worsham MJ, Benninger MS, et al. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 1994;9:192–206.

    Article  PubMed  Google Scholar 

  23. Jin Y, Mertens F, Mandahl N, et al. Chromosome abnormalities in eighty-three head and neck squamous cell carcinomas: influence of culture conditions on karyotypic pattern. Cancer Res 1993;53:2140–2146.

    PubMed  CAS  Google Scholar 

  24. Mao L, Fan YH, Lotan R, Hong WK. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res 1996;56:5128–5131.

    PubMed  CAS  Google Scholar 

  25. Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM, Sidransky D. Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994;54:1152–1155.

    PubMed  CAS  Google Scholar 

  26. Sartor M, Steingrimsdottir H, Elamin F, et al. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer 1999;80:79–86.

    Article  PubMed  CAS  Google Scholar 

  27. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 1999;30:1221–1225.

    Article  PubMed  CAS  Google Scholar 

  28. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682–685.

    Article  PubMed  CAS  Google Scholar 

  29. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630–3633.

    PubMed  CAS  Google Scholar 

  30. Hogg RP, Honorio S, Martinez A, et al. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 2002;38:1585–1592.

    Article  PubMed  CAS  Google Scholar 

  31. Brzoska PM, Levin NA, Fu KK, et al. Frequent novel DNA copy number increase in squamous cell head and neck tumors. Cancer Res 1995;55:3055–3059.

    PubMed  CAS  Google Scholar 

  32. Berenson JR, Yang J, Mickel RA. Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas. Oncogene 1989;4:1111–1116.

    PubMed  CAS  Google Scholar 

  33. Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer (Phila) 1994;74:152–158.

    Article  PubMed  CAS  Google Scholar 

  34. Jares P, Fernandez PL, Campo E, et al. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 1994;54:4813–4817.

    PubMed  CAS  Google Scholar 

  35. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003;95:198–205.

    Article  PubMed  CAS  Google Scholar 

  36. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824–832.

    Article  Google Scholar 

  37. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factoralpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer (Phila) 1996;78:1284–1292.

    Article  CAS  Google Scholar 

  38. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350–7356.

    PubMed  CAS  Google Scholar 

  39. Barrandon Y, Green H. Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-alpha and epidermal growth factor. Cell 1987;50:1131–1137.

    Article  PubMed  CAS  Google Scholar 

  40. Chen P, Xie H, Sekar MC, Gupta K, Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 1994;127:847–857.

    Article  PubMed  CAS  Google Scholar 

  41. Sorrells DL, Ghali GE, Meschonat C, et al. Competitive PCR to detect eIF4E gene amplification in head and neck cancer. Head Neck 1999;21:60–65.

    Article  PubMed  CAS  Google Scholar 

  42. Sudbo J, Ristimaki A, Sondresen JE, et al. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2003;39:497–505.

    Article  PubMed  CAS  Google Scholar 

  43. Patturajan M, Nomoto S, Sommer M, et al. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002;1:369–379.

    Article  PubMed  CAS  Google Scholar 

  44. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002;21:4231–4236.

    Article  PubMed  CAS  Google Scholar 

  45. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892–895.

    PubMed  CAS  Google Scholar 

  46. Rosas SL, Koch W, da Costa Carvalho MG, et al. Promoter hypermethylation patterns of p16, O-6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;61:939–942.

    PubMed  CAS  Google Scholar 

  47. Viswanathan M, Tsuchida N, Shanmugam G. Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer 2003;105:41–46.

    Article  PubMed  CAS  Google Scholar 

  48. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488–2492.

    PubMed  CAS  Google Scholar 

  49. Sudbo J, Lippman SM, Lee JJ, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004;350:1405–1413.

    Article  PubMed  CAS  Google Scholar 

  50. Sudbo J, Kildal W, Johannessen AC, et al. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol 2002;20:456–462.

    Article  PubMed  Google Scholar 

  51. Sudbo J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270–1278.

    Article  PubMed  CAS  Google Scholar 

  52. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become antiangiogenic. Am J Pathol 1996;149:247–258.

    PubMed  CAS  Google Scholar 

  53. Schultz-Hector S, Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res 1993;53:1444–1449.

    PubMed  CAS  Google Scholar 

  54. Gleich LL, Srivastava L, Gluckman JL. Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer. Ann Otol Rhinol Laryngol 1996;105:710–712.

    PubMed  CAS  Google Scholar 

  55. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997;33:369–374.

    Article  PubMed  CAS  Google Scholar 

  56. Petruzzelli GJ, Benefield J, Taitz AD, et al. Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferations. Head Neck 1997;19:576–582.

    Article  PubMed  CAS  Google Scholar 

  57. Kotwall C, Sako K, Razack M, et al. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 1987;154:439.

    Article  PubMed  CAS  Google Scholar 

  58. Pauloski BR, Rademaker AW, Logemann JA, et al. Pretreatment swallowing function in patients with head and neck cancer. Head Neck 2000;22:474–482.

    Article  PubMed  CAS  Google Scholar 

  59. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000;55:121–129.

    Article  PubMed  CAS  Google Scholar 

  60. Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 2001;50:727–733.

    Article  PubMed  CAS  Google Scholar 

  61. Jereczek-Fossa BA, Jassem J, Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 2004;30:153–164.

    Article  PubMed  Google Scholar 

  62. Stoeckli SJ, Zimmermann R, Schmid S. Role of routine panendoscopy in cancer of the upper aerodigestive tract. Otolaryngol Head Neck Surg 2001;124:208–212.

    Article  PubMed  CAS  Google Scholar 

  63. Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer (Phila) 1995;75:1343–1353.

    Article  PubMed  CAS  Google Scholar 

  64. Haughey BH, Gates GA, Arfken CL, Harvey J. Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol 1992;101:105–112.

    PubMed  CAS  Google Scholar 

  65. Johnson RE, Sigman JD, Funk GF, Robinson RA, Hoffman HT. Quantification of surgical margin shrinkage in the oral cavity. Head Neck 1997;19:281–286.

    Article  PubMed  CAS  Google Scholar 

  66. Ball VA, Righi PD, Tejada E, Radpour S, Pavelic ZP, Gluckman JL. p53 immunostaining of surgical margins as a predictor of local recurrence in squamous cell carcinoma of the oral cavity and oropharynx. Ear Nose Throat J 1997;76:818–823.

    PubMed  CAS  Google Scholar 

  67. Nathan CA, Franklin S, Abreo FW, et al. Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Laryngoscope 1999;109:1253–1258.

    Article  PubMed  CAS  Google Scholar 

  68. Robbins K. Neck dissection. In: Cummings C, Frederickson J, Harker L, Krause C, Schuller D (eds). Otolaryngology Head and Neck Surgery. St. Louis: Mosby-Year Book, 1998:1787.

    Google Scholar 

  69. Mira E, Benazzo M, Rossi V, Zanoletti E. Efficacy of selective lymph node dissection in clinically negative neck. Otolaryngol Head Neck Surg 2002;127:279–283.

    Article  PubMed  Google Scholar 

  70. Pitman KT, Johnson JT, Brown ML, Myers EN. Sentinel lymph node biopsy in head and neck squamous cell carcinoma. Laryngoscope 2002;112:2101–2113.

    Article  PubMed  Google Scholar 

  71. Mukherji SK, Armao D, Joshi VM. Cervical nodal metastases in squamous cell carcinoma of the head and neck: what to expect. Head Neck 2001;23:995–1005.

    Article  PubMed  CAS  Google Scholar 

  72. Chao KS, Wippold FJ, Ozyigit G, Tran BN, Dempsey JF. Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. Int J Radiat Oncol Biol Phys 2002;53:1174–1184.

    Article  PubMed  Google Scholar 

  73. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:23–28.

    Article  PubMed  Google Scholar 

  74. Milano M, Vokes E, Witt M, et al. Retrospective comparison of intensity modulated radiation therapy (IMRT) and conventional three-dimensional RT (3DCRT) in advanced head and neck patients treated with definitive chemoradiation. Proc Am Soc Clin Oncol 2003;22:499 (abstract 2007).

    Google Scholar 

  75. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;49:907–916.

    Article  PubMed  CAS  Google Scholar 

  76. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695–704.

    Article  PubMed  CAS  Google Scholar 

  77. Butler EB, Teh BS, Grant WH III, et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 1999;45:21–32.

    Article  PubMed  CAS  Google Scholar 

  78. Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2000;46:1117–1126.

    Article  PubMed  CAS  Google Scholar 

  79. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 2003;57:49–60.

    Article  PubMed  Google Scholar 

  80. Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993;26:3–11.

    PubMed  CAS  Google Scholar 

  81. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571–578.

    Article  PubMed  CAS  Google Scholar 

  82. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111–121.

    Article  PubMed  CAS  Google Scholar 

  83. Jackson SM, Weir LM, Hay JH, Tsang VH, Durham JS. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;43:39–46.

    Article  PubMed  CAS  Google Scholar 

  84. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123–136.

    Article  PubMed  CAS  Google Scholar 

  85. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933–940.

    Article  PubMed  Google Scholar 

  86. Skladowski K, Maciejewski B, Golen M, Pilecki B, Przeorek W, Tarnawski R. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer: report on 3-year tumour control and normal tissue toxicity. Radiother Oncol 2000;55:101–110.

    Article  PubMed  CAS  Google Scholar 

  87. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22:1743–1752.

    Article  PubMed  Google Scholar 

  88. Lamont EB, Vokes EE. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol 2001;2:261–269.

    Article  PubMed  CAS  Google Scholar 

  89. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995;13:1493–1500.

    PubMed  Google Scholar 

  90. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245–1251.

    PubMed  CAS  Google Scholar 

  91. Sessions DG, Spector GJ, Lenox J, et al. Analysis of treatment results for floor-of-mouth cancer. Laryngoscope 2000;110:1764–1772.

    Article  PubMed  CAS  Google Scholar 

  92. Sessions DG, Spector GJ, Lenox J, Haughey B, Chao C, Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope 2002;112:616–625.

    Article  PubMed  Google Scholar 

  93. O’Brien CJ, Lauer CS, Fredricks S, et al. Tumor thickness influences prognosis of T1 and T2 oral cavity cancer—but what thickness? Head Neck 2003;25:937–945.

    Article  PubMed  Google Scholar 

  94. Kowalski LP. Results of salvage treatment of the neck in patients with oral cancer. Arch Otolaryngol Head Neck Surg 2002;128:58–62.

    PubMed  Google Scholar 

  95. Wax MK, Bascom DA, Myers LL. Marginal mandibulectomy vs. segmental mandibulectomy: indications and controversies. Arch Otolaryngol Head Neck Surg 2002;128:600–603.

    PubMed  Google Scholar 

  96. Moore BA, Magdy E, Netterville JL, Burkey BB. Palatal reconstruction with the palatal island flap. Laryngoscope 2003;113:946–951.

    Article  PubMed  Google Scholar 

  97. Landes CA, Kovacs AF. Nine-year experience with extended use of the commissure-based buccal musculomucosal flap. Plast Reconstr Surg 2003;111:1029–1039; discussion 1040–1042.

    Article  PubMed  Google Scholar 

  98. Harrison LB, Zelefsky MJ, Armstrong JG, Carper E, Gaynor JJ, Sessions RB. Performance status after treatment for squamous cell cancer of the base of tongue-a comparison of primary radiation therapy versus primary surgery. Int J Radiat Oncol Biol Phys 1994;30:953–957.

    PubMed  CAS  Google Scholar 

  99. Robertson ML, Gleich LL, Barrett WL, Gluckman JL. Base-of-tongue cancer: survival, function, and quality of life after external-beam irradiation and brachytherapy. Laryngoscope 2001;111:1362–1365.

    Article  PubMed  CAS  Google Scholar 

  100. Azizzadeh B, Enayati P, Chhetri D, et al. Long-term survival outcome in transhyoid resection of base of tongue squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2002;128:1067–1070.

    PubMed  Google Scholar 

  101. Galati LT, Myers EN, Johnson JT. Primary surgery as treatment for early squamous cell carcinoma of the tonsil. Head Neck 2000;22:294–296.

    Article  PubMed  CAS  Google Scholar 

  102. Perlmutter MA, Johnson JT, Snyderman CH, Cano ER, Myers EN. Functional outcomes after treatment of squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 2002;128:887–891.

    PubMed  Google Scholar 

  103. Zeitels SM, Vaughan CW, Ruh S. Suprahyoid pharyngotomy for oropharynx cancer including the tongue base. Arch Otolaryngol Head Neck Surg 1991;117:757–760.

    PubMed  CAS  Google Scholar 

  104. Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 2003;129:36–43.

    Article  PubMed  Google Scholar 

  105. Eckel HE, Staar S, Volling P, Sittel C, Damm M, Jungehuelsing M. Surgical treatment for hypopharynx carcinoma: feasibility, mortality, and results. Otolaryngol Head Neck Surg 2001;124:561–569.

    Article  PubMed  CAS  Google Scholar 

  106. Czaja JM, Gluckman JL. Surgical management of early-stage hypopharyngeal carcinoma. Ann Otol Rhinol Laryngol 1997;106:909–913.

    PubMed  CAS  Google Scholar 

  107. Julieron M, Kolb F, Schwaab G, et al. Surgical management of posterior pharyngeal wall carcinomas: functional and oncologic results. Head Neck 2001;23:80–86.

    Article  PubMed  CAS  Google Scholar 

  108. Laccourreye O, Merite-Drancy A, Brasnu D, et al. Supracricoid hemilaryngopharyngectomy in selected pyriform sinus carcinoma staged as T2. Laryngoscope 1993;103:1373–1379.

    Article  PubMed  CAS  Google Scholar 

  109. Steiner W, Ambrosch P, Hess CF, Kron M. Organ preservation by transoral laser microsurgery in piriform sinus carcinoma. Otolaryngol Head Neck Surg 2001;124:58–67.

    Article  PubMed  CAS  Google Scholar 

  110. Smith JC, Johnson JT, Myers EN. Management and outcome of early glottic carcinoma. Otolaryngol Head Neck Surg 2002;126:356–364.

    Article  PubMed  Google Scholar 

  111. Gallo A, de Vincentiis M, Manciocco V, Simonelli M, Fiorella ML, Shah JP. CO2 laser cordectomy for early-stage glottic carcinoma: a long-term follow-up of 156 cases. Laryngoscope 2002;112:370–374.

    Article  PubMed  Google Scholar 

  112. Pradhan SA, Pai PS, Neeli SI, D’Cruz AK. Transoral laser surgery for early glottic cancers. Arch Otolaryngol Head Neck Surg 2003;129:623–625.

    Article  PubMed  Google Scholar 

  113. Tamura E, Kitahara S, Ogura M, Kohno N. Voice quality after laser surgery or radiotherapy for T1a glottic carcinoma. Laryngoscope 2003;113:910–914.

    Article  PubMed  Google Scholar 

  114. Pearson BW, Salassa JR. Transoral laser microresection for cancer of the larynx involving the anterior commissure. Laryngoscope 2003;113:1104–1112.

    Article  PubMed  Google Scholar 

  115. Hartig G, Truelson J, Weinstein G. Supraglottic cancer. Head Neck 2000;22:426–434.

    Article  PubMed  CAS  Google Scholar 

  116. Scola B, Fernandez-Vega M, Martinez T, Fernandez-Vega S, Ramirez C. Management of cancer of the supraglottis. Otolaryngol Head Neck Surg 2001;124:195–198.

    Article  PubMed  CAS  Google Scholar 

  117. Iro H, Waldfahrer F, Altendorf-Hofmann A, Weidenbecher M, Sauer R, Steiner W. Transoral laser surgery of supraglottic cancer: follow-up of 141 patients. Arch Otolaryngol Head Neck Surg 1998;124:1245–1250.

    PubMed  CAS  Google Scholar 

  118. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–1952.

    Article  PubMed  CAS  Google Scholar 

  119. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937–1944.

    Article  PubMed  Google Scholar 

  120. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091–2098.

    Article  PubMed  CAS  Google Scholar 

  121. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685–1690.

    Google Scholar 

  122. Haraf DJ, Kies M, Rademaker AW, et al. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol 1999;17:638–644.

    PubMed  CAS  Google Scholar 

  123. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890–899.

    Article  PubMed  CAS  Google Scholar 

  124. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949–955.

    PubMed  CAS  Google Scholar 

  125. Fu KK, Phillips TL, Silverberg IJ, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410–1418.

    PubMed  CAS  Google Scholar 

  126. Shanta V, Krishnamurthi S. Combined bleomycin and radiotherapy in oral cancer. Clin Radiol 1980;31:617–620.

    Article  PubMed  CAS  Google Scholar 

  127. Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol 1997;15:268–276.

    PubMed  CAS  Google Scholar 

  128. Al-Sarraf M, Pajak TF, Marcial VA, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer (Phila) 1987;59:259–265.

    Article  PubMed  CAS  Google Scholar 

  129. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22(14):2856–2864.

    Article  PubMed  CAS  Google Scholar 

  130. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652–1661.

    PubMed  CAS  Google Scholar 

  131. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961–1969.

    PubMed  CAS  Google Scholar 

  132. Adelstein DJ, Saxton JP, Lavertu P, et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002;20:1405–1410.

    Article  PubMed  Google Scholar 

  133. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320–326.

    Article  PubMed  Google Scholar 

  134. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 2003;9:5936–5943.

    PubMed  CAS  Google Scholar 

  135. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002;20:3964–3971.

    Article  PubMed  Google Scholar 

  136. Medina JE. A rational classification of neck dissections. Otolaryngol Head Neck Surg 1989;100:169–176.

    PubMed  CAS  Google Scholar 

  137. Zbar RI, Funk GF, McCulloch TM, Graham SM, Hoffman HT. Pectoralis major myofascial flap: a valuable tool in contemporary head and neck reconstruction. Head Neck 1997;19:412–418.

    Article  PubMed  CAS  Google Scholar 

  138. Bastian RW, Park AH. Suction drain management of salivary fistulas. Laryngoscope 1995;105:1337–1341.

    Article  PubMed  CAS  Google Scholar 

  139. Ackerstaff AH, Hilgers FJ, Meeuwis CA, et al. Multi-institutional assessment of the Provox 2 voice prosthesis. Arch Otolaryngol Head Neck Surg 1999;125:167–173.

    PubMed  CAS  Google Scholar 

  140. Urken ML, Biller HF. A new bilobed design for the sensate radial forearm flap to preserve tongue mobility following significant glossectomy. Arch Otolaryngol Head Neck Surg 1994;120:26–31.

    PubMed  CAS  Google Scholar 

  141. Lyos AT, Evans GR, Perez D, Schusterman MA. Tongue reconstruction: outcomes with the rectus abdominis flap. Plast Reconstr Surg 1999;103:442–447; discussion 448–449.

    Article  PubMed  CAS  Google Scholar 

  142. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980–1987.

    Article  PubMed  CAS  Google Scholar 

  143. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77–85.

    Article  PubMed  CAS  Google Scholar 

  144. Burtness B, Li Y, Flood W, Mattar B, Forastiere A. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 2002;21:226a (abstract 901).

    Google Scholar 

  145. Sudbo J, Reith A. Which putatively pre-malignant oral lesions become oral cancers? Clinical relevance of early targeting of high-risk individuals. J Oral Pathol Med 2003;32:63–70.

    Article  PubMed  Google Scholar 

  146. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405–1410.

    Article  PubMed  CAS  Google Scholar 

  147. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501–1505.

    Article  PubMed  CAS  Google Scholar 

  148. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795–801.

    Article  PubMed  CAS  Google Scholar 

  149. Khuri FLJ, Lippman SM, Kim ES, et al. Isotretinoin effects on head and neck cancer recurrence and second primary tumors. In: American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2003, vol 22.

    Google Scholar 

  150. Pinto HLY, Loprinzi C, Kardinal C, Adams G, Pandya K. Phase III trial of low-dose 13-cis-retinoic acid for prevention of second primary cancers in stage I–II head and neck cancer: an Eastern Cooperative Oncology Group Study. In: American Society of Clinical Oncology Annual Meeting, San Francisco, CA, 2001, vol 20.

    Google Scholar 

  151. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001;19:3010–3017.

    PubMed  CAS  Google Scholar 

  152. Papadimitrakopoulou VA, Clayman GL, Shin DM, et al. Biochemoprevention for dysplastic lesions of the upper aero-digestive tract. Arch Otolaryngol Head Neck Surg 1999;125:1083–1089.

    PubMed  CAS  Google Scholar 

  153. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003;21:4546–4552.

    Article  PubMed  CAS  Google Scholar 

  154. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002;24:792–799.

    Article  PubMed  Google Scholar 

  155. Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000;6:4684–4691.

    PubMed  CAS  Google Scholar 

  156. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001;345:1877–1882.

    Article  PubMed  CAS  Google Scholar 

  157. Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 2000;6:1046–1051.

    PubMed  CAS  Google Scholar 

  158. Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59:5452–5455.

    PubMed  CAS  Google Scholar 

  159. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int J Cancer 2000;85:358–363.

    Article  CAS  Google Scholar 

  160. Lee AW, Foo W, Mang O, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980–99): an encouraging reduction in both incidence and mortality. Int J Cancer 2003;103:680–685.

    Article  PubMed  CAS  Google Scholar 

  161. Zeng YX, Jia WH. Familial nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:443–450.

    Article  PubMed  CAS  Google Scholar 

  162. Xiong W, Zeng ZY, Xia JH, et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 2004;64:1972–1974.

    Article  PubMed  CAS  Google Scholar 

  163. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet 1997;350:1087–1091.

    Article  PubMed  CAS  Google Scholar 

  164. Altun M, Fandi A, Dupuis O, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995;32:859–877.

    Article  PubMed  CAS  Google Scholar 

  165. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310–1317.

    PubMed  CAS  Google Scholar 

  166. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631–637.

    Article  PubMed  Google Scholar 

  167. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002;25:219–223.

    Article  PubMed  Google Scholar 

  168. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038–2044.

    Article  PubMed  CAS  Google Scholar 

  169. Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002;52:1238–1244.

    Article  PubMed  CAS  Google Scholar 

  170. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:1350–1357.

    PubMed  CAS  Google Scholar 

  171. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin)plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 1996;35:463–469.

    Google Scholar 

  172. Cummings C, Frederickson J, Harker L, Krause C, Schuller D. Otolaryngology—Head & Neck Surgery, vol 4. St. Louis: Mosby, 1998:2908–2933.

    Google Scholar 

  173. Bhattacharyya N, Fried MP. Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg 2002;128:904–908.

    PubMed  Google Scholar 

  174. Hocwald E, Korkmaz H, Yoo GH, et al. Prognostic factors in major salivary gland cancer. Laryngoscope 2001;111:1434–1439.

    Article  PubMed  CAS  Google Scholar 

  175. Regis De Brito Santos I, Kowalski LP, Cavalcante De Araujo V, Flavia Logullo A, Magrin J. Multivariate analysis of risk factors for neck metastases in surgically treated parotid carcinomas. Arch Otolaryngol Head Neck Surg 2001;127:56–60.

    PubMed  CAS  Google Scholar 

  176. Zbaren P, Schar C, Hotz MA, Loosli H. Value of fine-needle aspiration cytology of parotid gland masses. Laryngoscope 2001;111:1989–1992.

    Article  PubMed  CAS  Google Scholar 

  177. Urquhart A, Hutchins LG, Berg RL. Preoperative computed tomography scans for parotid tumor evaluation. Laryngoscope 2001;111:1984–1988.

    Article  PubMed  CAS  Google Scholar 

  178. Greene F, Page D, Fleming I, et al. TNM Classification of Malignant Tumours. AJCC Cancer Staging Handbook. New York: Springer-Verlag, 2002:145–153.

    Google Scholar 

  179. Dulguerov P, Marchal F, Lehmann W. Postparotidectomy facial nerve paralysis: possible etiologic factors and results with routine facial nerve monitoring. Laryngoscope 1999;109:754–762.

    Article  PubMed  CAS  Google Scholar 

  180. Terrell JE, Kileny PR, Yian C, et al. Clinical outcome of continuous facial nerve monitoring during primary parotidectomy. Arch Otolaryngol Head Neck Surg 1997;123:1081–1087.

    PubMed  CAS  Google Scholar 

  181. Reddy PG, Arden RL, Mathog RH. Facial nerve rehabilitation after radical parotidectomy. Laryngoscope 1999;109:894–899.

    Article  PubMed  CAS  Google Scholar 

  182. Govindaraj S, Cohen M, Genden EM, Costantino PD, Urken ML. The use of acellular dermis in the prevention of Frey’s syndrome. Laryngoscope 2001;111:1993–1998.

    Article  PubMed  CAS  Google Scholar 

  183. Guntinas-Lichius O. Increased botulinum toxin type A dosage is more effective in patients with Frey’s syndrome. Laryngoscope 2002;112:746–749.

    Article  PubMed  CAS  Google Scholar 

  184. Arad-Cohen A, Blitzer A. Botulinum toxin treatment for symptomatic Frey’s syndrome. Otolaryngol Head Neck Surg 2000;122:237–240

    Article  PubMed  CAS  Google Scholar 

  185. Laskawi R, Drobik C, Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey’s syndrome). Laryngoscope 1998;108:381–384.

    Article  PubMed  CAS  Google Scholar 

  186. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 2001;111:218–226.

    Article  PubMed  CAS  Google Scholar 

  187. A phase III randomised trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer 1990;61:311–315.

    Google Scholar 

  188. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257–263.

    PubMed  CAS  Google Scholar 

  189. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521–526.

    PubMed  CAS  Google Scholar 

  190. Forastiere AA, Shank D, Neuberg D, Taylor SGt, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer (Phila) 1998;82:2270–2274.

    Article  PubMed  CAS  Google Scholar 

  191. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672–1678.

    PubMed  CAS  Google Scholar 

  192. Couteau C, Chouaki N, Leyvraz S, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999;81:457–462.

    Article  PubMed  CAS  Google Scholar 

  193. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533–537.

    PubMed  CAS  Google Scholar 

  194. Buesa JM, Fernandez R, Esteban E, et al. Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 1991;2:151–152.

    PubMed  CAS  Google Scholar 

  195. Huber MH, Lippman SM, Benner SE, et al. A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 1996;19:379–382.

    Article  PubMed  CAS  Google Scholar 

  196. Sandler A, Saxman S, Bandealy M, et al. Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial. Am J Clin Oncol 1998;21:195–197.

    Article  PubMed  CAS  Google Scholar 

  197. Cervellino JC, Araujo CE, Pirisi C, Francia A, Cerruti R. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study. Oncology 1991;48:89–92.

    PubMed  CAS  Google Scholar 

  198. Degardin M, Oliveira J, Geoffrois L, et al. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1998;9:1103–1107.

    Article  PubMed  CAS  Google Scholar 

  199. Saxman S, Mann B, Canfield V, Loehrer P, Vokes E. A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 1998;21:398–400.

    Article  PubMed  CAS  Google Scholar 

  200. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:543–547.

    PubMed  CAS  Google Scholar 

  201. Samlowski WE, Gundacker H, Kuebler JP, et al. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study. Invest New Drugs 2001;19:311–315.

    Article  PubMed  CAS  Google Scholar 

  202. Schrijvers D, Johnson J, Jiminez U, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol 1998;16:1054–1059.

    PubMed  CAS  Google Scholar 

  203. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001;19:1088–1095.

    PubMed  CAS  Google Scholar 

  204. Gilson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the eastern cooperative oncology group. J Clin Oncol 2005;23:3562–3567.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA

    Ezra E.W. Cohen MD (Assistant Professor)

  2. Department of Surgery, Section of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of Chicago, Chicago, IL, USA

    Kerstin M. Stenson MD, FACS (Associate Professor)

  3. Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA

    Michael Milano MD (Chief Resident)

  4. University of Chicago, Chicago, IL, USA

    Everett E. Vokes MD (Director, Section of Hematology/Oncology, John E. Ultmann Professor of Medicine and Radiation and Cellular Oncology)

Authors
  1. Ezra E.W. Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerstin M. Stenson MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Milano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Everett E. Vokes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgery Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Alfred E. Chang MD (Hugh Cabot Professor of Surgery and Chief) (Hugh Cabot Professor of Surgery and Chief)

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Daniel F. Hayes MD (Clinical Director) (Clinical Director)

  3. Department of Cardiothoracic Surgery, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  4. Thoracic Oncology, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  5. Department of Medicine, Harvard Medical School, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  6. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  7. Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  8. Schools of Public Health and Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  9. Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Timothy J. Kinsella MD (Vincent K. Smith Professor and Chairman) (Vincent K. Smith Professor and Chairman)

  10. Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

    Joan H. Schiller MD (Melanie Heald Professor of Medical Oncology) (Melanie Heald Professor of Medical Oncology)

  11. Health Media Research Laboratory, Department of Health Behavior and Health Education, University of Michigan School of Public Health, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

  12. Cancer Prevention and Control, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Cohen, E.E., Stenson, K.M., Milano, M., Vokes, E.E. (2006). Head and Neck Cancer. In: Chang, A.E., et al. Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-31056-8_36

Download citation

  • DOI: https://doi.org/10.1007/0-387-31056-8_36

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24291-0

  • Online ISBN: 978-0-387-31056-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation